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Abstract
Insertion of bone substitution materials accelerates healing of osteoporotic fractures. Biodegradable materials are
preferred  for  application  in  osteoporotic  patients  to  avoid  a  second  surgery  for  implant  replacement.  Degraded
implant fragments are often absorbed by macrophages that are removed from the fracture side via passage through
veins or lymphatic vessels. We investigated if lymphatic vessels occur in osteoporotic bone defects and whether they
are regulated by the use of different materials. To address this issue osteoporosis was induced in rats using the
classical method of bilateral ovariectomy and additional calcium and vitamin deficient diet. In addition, wedge-shaped
defects of 3, 4, or 5 mm were generated in the distal metaphyseal area of femur via osteotomy. The 4 mm defects
were subsequently used for implantation studies where bone substitution materials of calcium phosphate cement,
composites of collagen and silica, and iron foams with interconnecting pores were inserted. Different materials were
partly additionally functionalized by strontium or bisphosphonate whose positive effects in osteoporosis treatment are
well known. The lymphatic vessels were identified by immunohistochemistry using an antibody against podoplanin.
Podoplanin  immunopositive  lymphatic  vessels  were  detected  in  the  granulation  tissue  filling  the  fracture  gap,
surrounding the implant and growing into the iron foam through its interconnected pores. Significant more lymphatic
capillaries were counted at the implant interface of composite, strontium and bisphosphonate functionalized iron
foam. A significant increase was also observed in the number of lymphatics situated in the pores of strontium coated
iron foam. In conclusion, our results indicate the occurrence of lymphatic vessels in osteoporotic bone. Our results
show  that  lymphatic  vessels  are  localized  at  the  implant  interface  and  in  the  fracture  gap  where  they  might  be
involved in the removal of lymphocytes, macrophages, debris and the implants degradation products. Therefore the
lymphatic vessels are involved in implant integration and fracture healing.
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Introduction
The insertion of bone substitution materials has been proven
to accelerate healing of osteoporotic fractures. Osteoporosis is
a  systemic  disease  with  a  characteristic  decrease  of  bone
strength and therefore an increase in fracture risk [1]. Usually,
postmenopausal women and aged men contract this disease.
Because of the demographic trend elderly people will increase
in the population which is why in future more people will suffer
from  osteoporosis  and  osteoporotic  fractures  [1].  The
commercially  available  bone  substitution  materials  are  not
etiology-adapted  and  therefore  not  appropriate  for  the
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has been worked out that modification with strontium [2], [3],
bisphosphonate  [4]  as  well  as  enhanced  resorption  capacity
and  changes  from  solid  material  to  interconnected  porous
material  [5]  improves  the  materials.  High  resorption  capacity
goes along with the disposal of the degraded fragments often
inserted  in  cell  organelles  of  macrophages.  Macrophages
containing  biomaterials  in  intracellular  vesicles  are  able  to
differentiate  into  osteoclasts  which  are  responsible  for  bone
resorption [6]. Macrophages are usually removed via veins and
lymphatic vessels [7]. The lymphatic network begins with the
lymphatic  capillaries  in  the  peripheral  tissues  that  transport
lymph  to  the  venous  system  via  passage  through  several
regional  and  collective  lymph  nodes.  Lymph  consists  of
interstitial  fluid,  lymphocytes,  and  macrophages.  Lymphatic
capillaries  differ  from  vascular  capillaries  in  their  larger
diameter,  irregular  outline,  thinner  walls,  incomplete  basal
membrane,  overlapping  endothelial  cells,  and  molecular
composition  of  their  endothelial  cells  [7].  In  the  last  years
several  markers  have  been  identified,  that  are  qualified  for
identification of lymphatic vessels [8]. The aim of the present
study was to identify the lymphatic vessels in a rat model of
osteoporotic  fractures  which  were  stabilized  by  newly
established bone substitution materials. Therefore, we recently
established a fracture defect model in the distal metaphyseal
area of the femur of osteoporotic rats [9-11]. We decided to use
small  animals  in  this  first  approach  because  of  the  shorter
breeding cycles, easier and less expensive animal housing that
allowed  us  to  investigate  several  different  bone  substitution
materials. A follow up study in a large animal model (e.g. ovine
model) where only the most suitable biomaterials from this first
study will be integrated would be very helpful because of the
closer mimic of large animals to the situation in humans. Rat
lymphatic  vessels  were  detected  by  immunohistochemical
staining  with  a  monoclonal  antibody  against  podoplanin.
Podoplanin is an integral membrane glycoprotein [12] that was
first  identified  in  the  murine  osteoblast  cell  line  MC3T3  [13].
Later  it  was  clarified  that  podoplanin  occurs  in  mature
osteoblasts  and  newly  formed  osteocytes  [14].  The  name
podoplanin is explained by its occurrence in podocytes of the
kidney [15], [16]. Besides it is also expressed in tumors (e.g.
[17], [18] [19], [20],), reticular and epithelial cells of lymphatic
tissues [21], alveolar type 1 cells of the lung [22], [23] [24],,
fibroblasts  and  premalignant  keratinocytes  of  skin  [19],  [25],
stromal cells of placenta [26], choroid plexus, ependymal and
neuronal  cells  of  brain  [27],  [28],  and  fibroblast-like
synoviocytes  in  rheumatoid  arthritis  [29].  Because  of  this
widespread distribution the protein is also well known under the
synonyms OTS-8 [13], E11 antigen [14], gp38 [21], T1α [22],
PA2.26  [19],  RANDAM-2  [28],  RTI40  [23],  and  Aggrus  [17].
Lymphatic  vessels  were  amongst  others  found  in  skeletal
muscle [30], heart [31], and during pathological conditions of
eye [32], skin [19], [25], and bone [7], [33]. Lymphatic vessels
were  absent  in  healthy  cancellous  and  cortical  bone  but
commonly exist in the periosteum and connective tissue [34],
[7].  Lymphatic  vessels  only  occur  in  bone  after  lesions,
fractures,  or  degenerations  [7],  [33].  It  is  supposed  that  the
lympahtics  are  spreading  from  the  periosteum  and  the
surrounding  connective  tissue  into  the  damaged  bone  area.
Lymphangiogenesis  is  stimulated  by  inflammatory  cytokines
because  of  its  function  in  transport  of  immune  cells  and
clearance  of  antigen  [35].  Pro-inflammatory  mediators  also
promote the formation of hematoma as one of the first steps of
fracture healing [36]. The hematoma is infiltrated by immune
competent  cells  (e.g.  lymphocytes,  granulocytes)  and
macrophages [36]. The duty of these cells is the removal of
debris  and  the  release  of  cytokines  and  growth  factors  that
promote fracture healing. Neutrophil granulocytes are usually
recruited by lymphocytes that afterwards leave the hematoma
through lymphatic vessels. Thus lymphatic vessels are usually
appearing  during  the  subsequent  stages  of  fracture  healing
where lymphocytes, neutrophils, and macrophages have to be
removed after they fulfilled their duty. However, there might be
a  relation  between  lymphangiogenesis  and  fracture  healing.
Implantation  of  bone  substitution  materials  leads  to  an
improved  fracture  healing.  If  bio-degradable  material  is  used
macrophages  are  involved  in  the  resorption  and  removal  of
degradation  products.  An  increase  in  macrophages  did  not
result  in  a  higher  number  of  lymphatic  vessels  [7].  Also  the
implantation  of  plain  hydroxyl  apatite  or  its  modification  with
platelet  factors  did  not  result  in  significant  differences  in  the
lymphangiogenesis  [7].  Nevertheless,  lymphatic  vessels
occurred in the granulations tissue after implantation of both
materials. On this background the aim of the present study was
to  investigate  if  lymphatic  vessels  occurred  in  systematically
diseased  bone  as  well  as  in  fracture  healing  and  implant
insertion in osteoporotic bone. Furthermore, we asked whether
the  choice  of  implant  material  influences  lymphangiogenesis.
The  obtained  results  might  help  for  further  improvement  of
implant materials.
Materials and Methods
Ethics Statement
All animal procedures were carried out in accordance to the
Guide for Care and Use of Laboratory Animals of the National
Institutes of Health. The study was approved by the local ethic
committee  (Regierungspräsidium  Gießen,  Permit  Number:  V
54 - 19c20-15 (1) GI 20/28, Nr. 92/2009). All efforts were made
to minimize suffering.
Animal model
We recently established a fracture defect model in the distal
femoral  metaphysis  of  osteoporotic  rats  [9-11].  In  brief,  14
week old female Spargue-Dawley rats (Charles River, Sulzfeld,
Germany) underwent laparotomy with subsequent removal of
ovaries under deep anaesthesia with i. p. injections of ketamine
(62.5 mg/kg bodyweight, Hostaket®, Hoechst) and xylazine (7.5
mg/kg bodyweight, Rompun®, Bayer). The animals were kept
under  a  12  h  light-dark  cycle  with  free  access  to  water  and
chow  that  were  specifically  produced  for  deficiency  diet  of
calcium,  vitamin  C/D2/D3,  and  phosphate  (Altromin-C1034,
Altromin-Spezialfutter  GmbH,  Lage,  Germany)  [10].  Again
under deep anesthesia a wedge-shaped methaphyseal fracture
of 3, 4, and 5 mm in diameter was performed at the left distal
femur 12 weeks of ovariectomy and the 4 mm defects were
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[9].  In  brief,  a  skin  incision  was  made,  a  7-hole  T-shaped
miniplate  (Leibinger®  XS-miniplate,  Stryker®,  Schönkirchen,
Germany) was fixed with 1.7 mm screws on the lateral femur,
and the defect was created, rinsed with sterile water, filled with
the  implant,  and  closed  in  multilayers  and  by  prolene  4/0
stitches. Always 7 animals got the same implant (groups) and
were sacrificed 6 weeks after surgery. Via the abdominal aorta
a  lead  containing  radio-opaque  polymer  (Microfil®  MV-122,
Flow Tech, Carver, MA, USA) was infused rinsing the vessels
with heparinized saline up to blood freeness (10 ml of 0.9 %
sodium chloride with 1000 LU heparin) [11]. In the histological
staining the polymerized Microfil® could be found in the lumen
of blood vessels.
Bone substitution materials
As implant materials calcium phosphate bone cement (CPC)
[37] that was composed of 58 wt% of α-tricalcium phosphate
[Ca3(PO4)2], 24 wt% dicalcium phosphate (CaHPO4), 8.5 wt%
precipitated  hydroxyapatite  [Ca10(PO4)6(OH)2],  and  8.5  wt%
calcium carbonate (CaCO3) was used plain and with strontium
modification (CPC-S). CPC-S was generated by replacement
of  CaCO3  with  strontium  carbonate  (SrCO3)  in  the  cement
precursor powder (Sr/Ca = 0.123) [38]. Implantation itself was
conducted  with  a  paste  formulation  of  the  cement  that  was
created by mixing with an aqueous solution of 4 % Na2HPO4.
Furthermore,  composites  consisting  of  silica  and  fibrillar
bovine  collagen  were  used  for  implantation  as  monolithic
xerogels (B30, 70 wt% silica, 30 wt% collagen) or as porous
scaffold  (pB30,  xerogel  particles  B30,  size  <  250  µm,
embedded in a collagen matrix with xerogel/matrix weight ratio
of  1.0)  [39],  [11],  [40].  A  modification  of  the  scaffolds  was
prepared by using xerogel particles consisting of 50 wt% silica,
30  wt%  fibrillar  bovine  collagen,  and  20  wt%  strontium
carbonate (pB30S20). Moreover, iron foam with interconnected
pores (Fe) was applied. The iron-foam was basically created of
carbonyl  iron,  Fe3-powder,  and  a  polyvinyl  alcohol  binder  by
powder-metallurgical  replication,  subsequent  sintering  at
1150°C,  and  shaping  by  wire  eroding.  The  iron  foam  was
coated with a) SrCO3 H3PO4 (Fe-S) under vacuum for 4 hours
(h) and rinsed afterwards with ethanol, and b) with zolendronic
acid (Fe-BP) that is a member of the bisphosphonate family.
Fe-BP  was  created  by  precipitation  of  zolendronic  acid,
stearate, and iron. Then, the complex was carefully washed,
dried,  grinded  and  finally  resulted  in  a  coating  of  35  µg
zolendronic  acid  on  the  basic  iron  foam.  These  8  different
formulations of bone substitution materials were implanted in
the current animal model.
Immunohistochemistry
Left  femora  were  fixed  in  4%  phosphate-buffered
paraformaldehyde  (Merck,  Darmstadt,  Germany),  dehydrated
through  a  series  of  ethanol  gradient,  embedded  in
methylmethacrylate (Technovit 9100, Heraeus Kulzer, Hanau,
Germany), and cut into slices with a thickness of 5 µm using a
rotations  microtome  (Leica  RM2155,  Wetzlar,  Germany).
Sections were deplasticized with 3-Methoxyethylacetat (MEA,
Merck, 3 x 20 min) and rehydrated through acetone and Tris-
NaCl buffer with 0.025 % Triton-X-100 (wash buffer, pH 7.4).
Endogenous peroxidase was blocked with 3 % H2O2 in wash
buffer for 5 min. Sections were incubated with primary mouse
monoclonal  anti  podoplanin  antibody  (antibodies-online,
Atlanta,  GA,  USA)  and  rabbit  anti  CD31  antibody  (Abbiotec,
San Diego, CA, USA) (dilution 1:8000 for podoplanin and 1:350
for CD31; dilution buffer was from Dako, Glostrup, Denmark) at
4°C  for  16  hours.  After  rinsing  in  wash  buffer  sections  were
incubated  with  biotinlated  horse-anti-mouse  secondary
antiserum  (dilution:  1:500)  and  goat  anti-rabbit  secondary
antiserum (dilution: 1:500) in Tris-NaCl with 1 % bovine serum
albumin  (Sigma,  Taufkirchen,  Deutschland)  and  12.5  %  rat
serum (PAA, Pasching, Austria) for 30 min. Afterwards sections
were  incubated  for  30  min  in  the  ABC  complex/horseradish
peroxidase  labeled  avidin  (Vector  laboratories,  Burlingame,
California, USA) with subsequent development of the staining
via  incubation  in  Nova  Red  (Vector  laboratories).
Counterstaining of nuclei was performed with hematoxylin (1:3
dilution;  Shandon  Scientific  Ltd,  Cheshire,  UK)  and
coverslipped with DePex (Serva, Heidelberg, Deutschland).
Quantification of lymphatic vessels
One  investigator  counted  the  lymphatic  vessels  manually
using an ocular micrometer. Additionally, a double blind study
was  conducted  where  a  second  investigator  confirmed  the
acquired  data.  The  lymphatic  vessels  were  quantified  in  the
whole fracture gap in sections with empty defects or without
residues  of  the  implants.  An  area  of  250  µm  at  the  implant
interface was analyzed if the implants remained or at least a
residual existed. In a separate set of examinations lymphatic
vessels  penetrating  the  iron  foam  were  counted.  A  manual
determination of the lymphatic vessels was necessary because
the  lymphatic  vessels  were  not  uniformly  distributed.  The
evaluation  was  conducted  with  a  20  x  objective  at  the  light
microscope (Zeiss, Jena, Germany).
Real-time RT-PCR
Tissue from the implant interface and the fracture gap was
collected in RNAlater immediately after scarification of animals.
Total RNA was isolated with the Lipid Tissue mini Kit (Qiagen,
Hilden,  Germany)  according  to  manufacturer’s  protocol.  In
brief, 100 mg of the sample was homogenized in 1 ml QIAzol
lysis reagents with a ultra-turrax (IKA, Staufen, Germany), 200
µl chloroform were added and centrifuged for 15 min at 4°C.
The RNA containing upper fraction was collected and washed
with  70  %  ethanol  and  Kit  buffer  RW1.  The  dried  RNA  was
resuspended  with  RNase-free  water  and  reverse  transcribed
with  the  Quantitect  Kit  (Qiagen).  Contaminations  of  genomic
DNA were removed using 2 µl DNA Wipeout buffer (component
of  the  Kit)  for  2  min  at  42°C.  Afterwards  1  µg  RNA  was
incubated  with  1  µl  Quantiscript  reverse  transcriptase,  4  µl
buffer  and  1  µl  primer  mix  containing  random-primers  and
Oligo(dT)s  at  42°  for  30  min.  The  reverse  transcriptase  was
inactivated at 95°C for 3 min. Real-time RT-PCR was carried
out  with  the  Light-Cycler  Fast  Start  DNA  Master  plus  SYBR
Green Kit (Roche Mannheim, Germany) in a Light Cycler 2.0
(Roche). 2 µl of cDNA, 2 µl Roche reagent (Kit component), 6.8
µl  RNase-free  water  and  0.2  µl  forward  and  reverse  primer
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incubated  for  10  min  at  95°C,  following  by  40  cycles  of  5
seconds  (s)  heating  at  95°C,  annealing  for  5  s  at  58°C  and
elongation for 5 s at 72°C. The PCR product was controlled by
melting curve and gel electrophoresis. As negative controls a)
reverse  transcription  was  carried  out  without  adding  the
enzyme  and  b)  water  was  used  instead  of  template  for
conducting PCR. Calculation of Cp-values was performed by
Light  Cycler  software.  For  quantification  Cp-values  of
podoplanin were normalized with the reference gene β-actin.
Statistical analysis
Statistical analysis was performed using the SPSS software
(version  21.0;  SPSS  Institute  Inc,  Cicago,  USA),  non-
parametric Kruskal-Wallis and Mann-Whitney tests. Confidence
level of p ≤ 0.05 was considered to be significant.
Results
Osteoporotic fracture model
Fractures  without  implanted  bone  substitution  material
showed a filling of the fractured gap with granulation tissue that
contained  several  lymphatic  vessels.  Since  we  investigated
different  fracture  sizes  (3,  4,  and  5  mm),  we  estimated  the
number of podoplanin immunopositive vessels in the fracture
gap.  The  mean  number  of  lymphatic  vessels  was  significant
lower in the subgroup with 4 mm defect size (25.83 ± 7.23) in
comparison to the 3 mm (64.83 ± 8.36) and 5 mm (97.00 ±
26.66)  defects,  respectively  (Figure  1).  The  3  mm  defect
contained a high amount of lymphatic vessels inside the small
remaining granulation tissue between the parts of the almost
bridged  fracture  gap  (Figure  2A-B).  The  4  mm  defect
represented a critical size defect with a fracture gap that was
filled  with  granulation  tissue  containing  only  a  few  lymphatic
vessels (Figure 2D-E) but a lot of blood vessels. The 5 mm
defect  showed  a  delayed  fracture  healing.  The  fracture  gap
was filled with a high amount of granulation tissue containing a
high number of lymphatic vessels but only limited blood vessels
(Figure 2G-H). Blood vessels were identified by a) filling with
Microfil®  (Figure  2D-E),  immunohistochemical  staining  of
vascular  endothelial  cells  using  an  antibody  against  CD31
(inset  in  Figure  2E),  the  absence  of  podoplanin
immunolabelling,  and  anatomical  characteristics  (Figure  2F).
Contrary  to  lymphatic  vessels  with  their  irregular  shape,  thin
and  discontinuous  walls  arteries  in  the  fracture  gap  were
identified by their regular shape and thicker walls because of
the muscle cells in the media (Figure 2F). Veins displayed a
broader  lumen  and  a  continuous  endothelium  in  contrast  to
lymphatic  vessels  in  the  fracture  gap  (Figure  2F).  The
podoplanin immunostaining was also detected in osteocytes of
the new build bone (Figure 2C). On mRNA level no regulation
was detected between the groups with different fracture size (3
mm, 4 mm and 5 mm, Figure 3)
CPC based implants
Two different formulations of the CPC based implants were
analyzed: a) plain CPC (CPC, Figure 4A-E) and b) strontium
functionalized  CPC  (CPC-S,  Figure  4F-G).  Six  weeks  after
surgery  the  implants  were  surrounded  by  granulation  tissue
that contained blood as well as lymphatic vessels (Figure 4A-
C). These two kinds of vessels were often found in association
(Figure  4C).  The  vasculature  was  not  equally  distributed
around the implant. Some of the CPC-S implants were already
fragmented (Figure 4F-G). Then, granulations tissue was found
Figure  1.    Number  of  lymphatic  vessels  in  empty
defects.  The 4 mm sized empty defect contained a significant
lower number of lymphatic vessels in comparison to the 3 mm
and 5 mm defects. The results are present as box plot where
the median is indicated by a solid line within the box, the 25th
and 75th percentile as bottom and top of the box, the 0th and
100th  percentile  as  lower  and  upper  whiskers,  respectively.
Small circles illustrate data beyond 3 x standard deviation (SD).
** = p ≤ 0.01.
doi: 10.1371/journal.pone.0077259.g001
Table 1. Primers used for RT-PCR.
targets   sequence length [bp] annealing [°C] Accession
β-actin fwd
1
TGTTACCAACTGGGACGACA 165 58 NM_007393.3
  rev2 GGGGTGTTGAAGGTCTCAAA      
Pdpn3 fwd ACCCCAATAGAGATAACGCAGG 75 58 NM_019358.1
  rev CCAGGGTCACTACAGCCAAG      
1. forward 2,reverse 3,Pdpn = podoplanin
doi: 10.1371/journal.pone.0077259.t001
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PLOS ONE | www.plosone.org 4 October 2013 | Volume 8 | Issue 10 | e77259Figure 2.  Podoplanin immunohistochemical staining in the rat osteoporotic fracture model.  The 3 mm (A) defect was
narrowed by new built bone (b) but the remaining granulation tissue (gt) contains a high number of lymphatic vessels (arrow in B).
Podoplanin positive osteocytes are localized in the new built bone (C). The 4 mm defect (D) is a typical critical size defect showing
no bridging of the fracture gap that was filled with granulation tissue (gt) with only a few lymphatics (arrow in E-F) but a lot of blood
vessels (stars). The vasculature was identified by Microfil® perfusion (stars in D-F), immunohistochemistry for CD31 (inset in E),
anatomical characteristics (F), and their absence of podoplanin immunreaction (F). The fracture gap of the 5 mm defect (C) was
filled with granulation tissue (gt) that contained a high amount of lymphatic vessels (arrow) but only limited blood vessels. Higher
magnification of lymphatics showed the irregular shape, the discontinuous endothelium, and thin walls in comparison to the thick
muscle  layer  in  the  walls  of  arteries  (Ar)  and  continuous  endothelium  and  wider  lumen  of  veins  (V  in  F).  The  nuclei  were
counterstained with hematoxylin. Bar: 1 mm in A, D, G, 200 µm in B, E, H, 20 µm in C, F and inset in E.
doi: 10.1371/journal.pone.0077259.g002
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(Figure 4G). The podoplanin immunoreactivity was also found
in  mature  osteoblasts  and  osteocytes  that  were  situated  in
adjacent  lacunae  surrounded  by  the  calcified  bone  matrix
(Figure 4B, D-F). The labeling was found in accordance to the
description  of  in  the  plasma  membrane  as  well  as  the
pseudopodia  of  osteocytes  that  were  situated  in  the  bone
canaliculi  (Figure  4D-E).  The  staining  intensity  of  lymphatic
vessels and osteocytes was similar (Figure 4B). No significant
differences  were  determined  for  the  number  of  lymphatic
vessels (Figure 5) as well as for the podoplanin expression by
comparing  CPC,  CPC-S  and  the  4  mm  empty  defect  that
served as control (Figure 6).
Composites of silica and collagen
Two types of the composite were used: monolithic xerogels
(B30,  Figure  7A-B)  and  porous  scaffolds  (pB30,  pB30S20,
Figure 7C-F), both with the dimension of a 4 mm wedge-shape
fitting exactly the fracture gap. After 6 weeks of implantation
the  residue  of  the  partially  resorbed  xerogel  (B30)  was
surrounded by granulation tissue that contained a high amount
of  cells  (Figure  7A).  Podoplanin  immunopositive  structures
were  found  at  the  direct  interface  of  the  implant  and,  in
addition,  penetrating  the  implant  (Figure  7B),  where  the
podoplanin  positive  structures  did  not  form  fully  developed
lymphatic vessels. It appeared like broken lines, a staining of
plasma  membrane  of  big  cells,  and  labeled  lymphatic
endothelial  cells  during  the  process  of  lymphangiogenesis
(Figure 7B).
In contrast no residues of the porous B30 bone substitution
material  could  be  found  in  the  fracture  gap  (Figure  7C).
Instead, the gap was filled with granulation tissue containing
Figure 3.  Expression of podoplanin in empty defects.  No
regulation of the podoplanin expression was detected for the
empty defects by means of real-time RT-PCR. The results are
presented as box plot with the median, the 0th, 25th, 75th, and
100th  percentile.  Small  circles  illustrate  data  beyond  3  x
standard deviation (SD).
doi: 10.1371/journal.pone.0077259.g003
several  fully  developed  podoplanin  immunopositiv  lymphatic
vessels (Figure 7D). The same situation was observed for the
strontium modified scaffolds (Figure 7E-F).
Comparing the number of lymphatic vessels we could neither
detect  significant  changes  between  the  different  composite
types nor between the porous scaffolds (pB30, pB30S20) and
the  empty  defect  (Figure  5).  The  xerogel  (B30)  exhibited  a
significant  (p  =  0.024)  increase  in  the  amount  of  lymphatic
vessels at its interface in comparison to the control group (4
mm empty defect) (Figure 5). No regulation of podoplanin was
found  comparing  xerogels,  porous  scaffolds,  and  the  4  mm
empty defect as appropriate control (Figure 6).
Iron foam implants
Three different formulations of the iron foam were used as
implant in the different rat groups: a) plain iron foam (Fe, Figure
8), b) strontium functionalized iron foam (Fe-S, Figure 9), and
c)  iron  foam  with  coating  of  the  bisphosphonate  zolendronic
acid  (Fe-BP,  Figure  10).  The  different  modifications  of  iron
foam were surrounded by granulation tissue after implantation
(Figure 8A, 9A, 10A). The granulation tissue contained a high
amount of fully developed lymphatic vessels (Figure 8B, 9B).
No  significant  differences  were  found  in  the  number  of
lymphatic  vessels  in  the  granulation  tissue  (Figure  5).  But  a
significant  increase  in  lymphatics  was  determined  for  the
modified iron foams (Fe-S, Fe-BP) in comparison to the empty
defect (4 mm) that served as control (p = 0.001 for Fe-S and p
= 0.026 for Fe-BP) (Figure 5). On mRNA level no significant
changes could be measured for podoplanin (Figure 6)
Several cells with yellow granular cytoplasm appeared in the
granulation  tissue  (Figure  8C,  9C-D,  10B-D).  This  yellow
staining could result from resorbed iron. However, these cells
are  often  localized  in  direct  contact  to  the  podoplanin
immunopositiv vessels (Figure 10B). Some of the yellow cells
were  also  observed  in  the  lumen  of  lymphatic  capillaries
(Figure 10C). In other lymphatic vessels we identified nuclei of
lymphocytes  (Figure  10D).  This  was  mainly  observed  at  the
interface of Fe-BP.
Moreover  lymphatic  vessels  were  also  localized  in  the
connecting pores of Fe and Fe-S but not in the Fe-BP group.
These  changes  in  the  amount  of  lymphatic  vessels  were
significant  (Figure  11,  p  =  0.004  and  p  =  0.001  for  the
comparison of Fe to Fe-S and of Fe-S to Fe-BP, respectively).
The pores of Fe-S were filled with granulation tissue whereas
the pores of Fe-BP were not integrated by connective tissue.
The interconnected pores of Fe implants were only filled with
granulations  tissue  near  the  interface.  Pores  situated  in  the
center of the implant were not filled with granulation tissue after
six  week  follow-up  time  and  therefore  no  lymphatic  vessels
occurred there.
Discussion
The  present  study  demonstrates  for  the  first  time  the
presence  of  lymphatic  vessels  in  an  osteoporosis  animal
model. Osteoporosis was induced by bilateral ovariectomy and
additional feeding with calcium, Vitamin C/D2/D3 and phosphate
restricted  diet  in  current  rat  model  [10].  This  treatment  is
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not affected by this disease [41]. Osteoporosis is described as
a systemic disease that causes an imbalance of the osteoblast
and  osteoclast  population  in  which  the  bone  degrading
osteoclasts  are  enhanced  [1].  Thereby  the  bone  mineral
density  is  reduced  that  accounts  for  the  increase  in  fracture
incidence  [1].  Recent  studies  determined  that  the  animals  in
the applied rat model suffer from a disease with reduced bone
mineral  density  as  measured  by  DXA  scan,  an  enhanced
fracture  risk  as  shown  by  biomechanical  analysis,  and  an
imbalance in bone synthesis and depletion [10], [42]. Therefore
the  rat  model  can  be  utilized  for  studying  aspects  that  are
connected  to  the  typical  human  disease  osteoporosis.
However, not only the fracture frequency is increased in this
illness, but also the fractures are different from such of bone-
healthy  patients.  Characteristically  osteoporotic  fractures  are
localized in the spongy bone of metaphyseal trabecular regions
[43],  [44]  like  vertebrae,  distal  radius,  proximal  femur  and
humerus [45], [46], [47]. Thus in the present study a wedge-
shaped defect in the distal metaphyseal area of the femur was
performed  [9,11].  We  did  not  dispose  the  proximal  femur
because of its bad accessibility. Utilizing the distal metaphyseal
Figure 4.  CPC based implants.  Podoplanin immunopositive lymphatic vessels (arrow) were localized in the granulation tissue (gt)
at the interface of the CPC implant (A-E) as well as at the strontium functionalized CPC (CPC-S in E-F) where an improved
fragmentation was found (F). Lympatics were often associated with blood vessels that were identified by Microfil® perfusion (star in
C).  Podoplanin  also  stained  osteocytes  (arrowhead  in  B-F)  and  mature  osteoblasts  (O).  Nuclei  were  counterstained  with
hematoxylin. m = bone substitution material. Bars: 1 mm in A, F, 200 µm in B, G, and 20 µm in C-E.
doi: 10.1371/journal.pone.0077259.g004
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effectively  resets  the  clinical  situation  of  an  osteoporotic
fracture as mainly known from aged postmenopausal female
patients [11], [9]. Even though an animal model can of course
not fully reflect the conditions of humans [41] the current model
can  be  used  for  analysis  of  some  basic  purposes  as  the
occurrence of lymphatics.
The focus of our investigation was the analysis of lymphatic
vessels that were identified by immunohistochemistry. Using a
monoclonal  antibody  against  podoplanin  the  discrimination
between lymphatic and blood vessels in histological sections is
possible  and  well  reproducible  [8].  Podoplanin  represents  a
type-1  transmembrane  sialomucin-like  glycoprotein  that  is
widely spread. In podocytes of kidney the protein is involved in
obtaining  cell  morphology  and  maintenance  in  glomerular
permeability  [16].  Up  to  now,  the  function  of  podoplanin  in
lymphatic  endothelial  cells  is  not  fully  understood.
Nevertheless, similar as in the podocytes the protein might be
involved  in  maintaining  the  cellular  shape  and  regulate  the
permeability of lymphatic vessels [15], [16].
Lymphatic  vessels  were  not  found  in  healthy  adult  bone
tissue  [7],  [33]  [34],  but  in  the  outer  periosteum  and  the
surrounding connective tissue [33]. They appear in pathological
situations  like  vertebral  destructions,  lesions,  infections,  and
degenerations  [33].  During  early  stages  of  defect  healing  a
hematoma is build up that is infiltrated by macrophages and
immune  competent  cells  (e.g.  lymphocytes,  granulocytes),
Figure 5.  Number of lymphatic vessels at the interface of
the  implant.    A  significant  up-regulation  was  found  for  the
silica-collagen  xerogel  (B30),  the  strontium  (Fe-S)  and
bisphosphonate  (Fe-BP)  functionalized  iron  foam  in
comparison to the negative control without implant. Data were
presented  as  box  plots  where  a  solid  line  within  the  box
indicated  the  median.  Small  circles  show  data  beyond  3  x
standard  deviation  (SD).  CPC  =  calcium  phosphate  cement,
CPC-S = strontium modified CPC, pB30 = composite scaffold,
pB30S20  =  strontium-modified  composite  scaffold,  B30  =
xerogel consisting of 70 wt% silica, 30 wt% collagen, Fe = iron
foam. * = p ≤ 0.05.
doi: 10.1371/journal.pone.0077259.g005 amongst  others  [36].  Thus,  it  was  not  surprising  to  find
lymphocytes  in  the  lumen  of  lymphatic  capillaries  of  some
animal groups in our implant study. An obvious enhancement
of  lymphocytes  inside  lymphatic  vessels  was  determined  in
groups of plain iron foam (Fe) and Fe-BP. We suppose that
these  two  groups  are  set  in  between  the  hematoma  and
granulation  stage  of  bone  healing.  The  implant  interface
already shows fully developed granulation tissue whereas the
implant pores were not filled (Fe-BP) or only partially filled (Fe)
with granulation tissue. This is contrary to Fe-S implants where
the  pores  were  completely  filled  with  granulations  tissue.
Hence  we  conclude  that  strontium  ameliorated  osseous
integration of iron foam and therefore fracture healing.
Besides,  lymphatic  vessels  are  supposed  to  remove
macrophages and their phagocytozed material from the implant
interface.  Since  macrophages  with  resorbed  wear  particles
from  prosthesis  were  found  in  lymph  nodes  it  has  been
assumed  that  the  implant  interface  is  cleared  via  lymphatic
circulation  [48],  [49],  [50].  The  removal  of  macrophages  that
are  containing  particles  of  resorbed  material  seems  to  be
important because it has been described that this cells are able
to  differentiate  into  osteoclasts  and  secrete  prostaglandins,
cytokines, and other factors that promote bone resorption [51],
[52]. However, in our earlier study we could not determine an
up-regulation  in  the  number  of  lymphatic  vessels  when  the
amount of resorbing macrophages increased because of high
fragmentation  of  the  implant  [7].  Similar  like  in  our  previous
study the quantification of lymph capillaries was conducted by
double  blind  counting.  However,  this  time  two  investigators
Figure  6.    Expression  of  podoplanin  at  the  implant
interface.    Using  real-time  RT-PCR,  no  regulation  of
podoplanin  at  the  mRNA  level  could  be  detected  in  the
interface area of the implant. The results are presented as box
plot  with  the  median,  the  0th,  25th,  75th,  and  100th  percentile.
Small circles illustrate data beyond 3 x standard deviation (SD).
CPC  =  calcium  phosphate  cement,  CPC-S  =  strontium
modified  CPC,  pB30  =  composite  scaffold,  pB30S20  =
strontium-modified  composite  scaffold,  B30  =  xerogel
consisting of 70 wt% silica, 30 wt% collagen, Fe = iron foam.
doi: 10.1371/journal.pone.0077259.g006
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implant and a region of 250 µm surrounding the implant, and
not only in few regions of interest because the vessels were not
uniformly  distributed.  In  addition,  the  occurrence  of  the
lymphatic  capillaries  could  not  be  compared  to  implant
orientation.  No  significant  accumulation  of  lymphatics  was
observed. In general, they were found in the granulation tissue
that  filled  the  fracture  gap,  surrounded  and  infiltrated  the
implant.
As  second  independent  method  for  quantification  we  used
real-time RT-PCR. However, using this method we could not
determine  any  significant  changes  (Figure  3  and  6)  in
podoplanin mRNA (between the different groups). We suspect
that  the  different  cell  populations  which  express  podoplanin
were  the  reason  for  these  unexpected  results.  In  addition  to
Figure 7.  Podoplanin immunoreactivity at composites assembled by silica, collagen (pB30, B30), and additional strontium
(pB30S20).    The  implanted  xerogel  (B30,  A-B)  was  surrounded  by  podoplanin  immunopositive  structures  that  were  related  to
developing lymphatic capillaries (arrow in B) and additional myofibroblasts (f in B). Some immunoreactivity was also found in the
implant (arrowhead and in higher magnification in the inset in A). No residues of the porous composite scaffolds (pB30, pB30S20)
were detected (C-F). Podoplanin labeled lymphatic vessels (arrow) were found in the granulation tissue (gt) of the fracture gap (C,
E). The lymphatics (arrow) were often localized close to blood vessels (stars in B, D) that were identified by their filling with Microfil®
(star). Nuclei were counterstained with hematoxylin. m = bone substitution material. Bar represents 200 µm in A, C, E and 20 µm in
inset of A, B, D, and F.
doi: 10.1371/journal.pone.0077259.g007
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osteoblasts  and  newly  developed  osteocytes  [14].  Thus,  in
real-time RT-PCR analysis for RNA isolated out of the whole
sample  it  is  not  possible  to  distinguish  between  lymphatic
vessels  and  the  osteoblast  lineage.  Therefore,  we  conclude
that this second method of quantification was in our case not
suitable for the assignation of the number of lymphatic vessels
whereas  it  was  well  implemented  in  other  studies  where  no
bone was found in the surrounding area [53].
In  the  first  part  of  our  study  we  performed  wedge-shaped
metaphysal fractures of 3 different sizes. The 3 mm defect was
partially  bridged  by  bone  containing  osteocyts  that  were
localized  in  adjacent  lacunae  surrounded  by  calcified  bone
matrix. Newly formed osteocytes as well as mature osteoblasts
are  podoplanin  immunopositive  [14].  Regardless  of  the  bony
bridge some granulation tissue remained and contained a high
number of lymphatic vessels inside a small area. The 4 and 5
mm wedge-shaped fractures represent critical size defects [9].
In  the  fracture  gap  of  the  5  mm  defect  only  new  build
Figure 8.  Podoplanin staining at the plain iron foam (Fe).  The interface of the wedge-shaped implant (m) was covered with
granulation tissue (gt) that infiltrated the interconnected pores (p) near the interface (A-B). Podoplanin immunopositive lymphatic
vessels (arrow) were found in the granulation tissue often close to the yellow cells with the resorbed iron (C). Granula of resorbed
iron (star) were found in lymphatic capillaries (D). Lymphatics were also situated next to iron fragments (arrowhead, E). Islets with
podoplanin  stained  osteocytes  were  detected  in  the  granulation  tissue  (F).  Nuclei  were  counterstained  with  hematoxylin.  Bar
represents 1 mm in A, 200 µm in B, 20 µm in C-D.
doi: 10.1371/journal.pone.0077259.g008
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The 4 mm fracture was narrowed by insular regions of newly
built bone and the granulation tissue contained a high number
of  blood  vessels.  The  bony  islands  were  surrounded  by
granulation tissue that included only few lymphatic capillaries.
Also only few lymphatic vessels were found in association with
the blood vasculature in the empty defect. Thus we counted for
the  4  mm  defect  a  significant  smaller  number  of  lymphatic
vessels in comparison to the 3 and 5 mm fractures. Our results
showed that examination of lymphatic vessels were providing
information  about  bone  healing.  However,  less  lymphatic
vessels  did  not  reflect  best  fracture  healing  as  might  be
assumed  because  of  the  absence  of  lympathic  vessels  in
undamaged bone.
For the second part of our study the 4 mm defects were used
to test the occurrence of lymphatic vessels at the interface of
bone  substitution  materials.  Applying  biomaterials  into  the
fracture gap has been proven to accelerate bone healing [54].
Since up to now none of the commercial available biomaterials
is  appropriate  for  the  usage  in  osteoporotic  bone  we
investigated the podoplainin immunolabeling after implantation
of several biomaterials. CPC is already well approved for the
administration  in  non-systemically  diseased  bone  tissue  [37].
To adapt CPC to the required conditions in osteoporosis it was
modified  with  strontium.  Because  of  the  systemic  nature  of
osteoporosis  it  is  not  possible  that  local  acting  biomaterials
themselves influence the illness but modifying them with drugs,
growth factors, organic and inorganic active components might
promise success. Recently it has been described that strontium
administration was successful for the treatment of osteoporosis
[2], [3]. Thus one animal subgroup received an implant with a
strontium modification of the CPC. At the implant interface of
both CPC groups only a few lymphatic vessels were found in
close proximity of blood vessels. No significant differences in
the number of lymphatic vessels were determined between the
two CPC groups themselves, nor in comparison to the control
group  (4  mm  defect).  In  some  animals  from  the  CPC-S
subgroup the fragmentation of the implant was upgraded and
subsequent  granulation  tissue  including  lymphatic  vessels
penetrated the implant. Thus, in some animals of the CPC-S
group  we  found  a  higher  amount  of  lymphatic  vessels.
Nonetheless,  no  significances  were  calculated  most  likely
because of the high variance between the individual animals. In
another subset of experiments composites consisting of silica
and  collagen  were  implanted  as  monolithic  xerogels  or  as
porous  scaffolds  containing  xerogel  particles  with  or  without
Figure 9.  Podoplanin immunohistochemistry at the implant of iron foam with a strontium coating (Fe-S).  Podoplanin
labeled lymphatic vessels (arrow) were found in the granulation tissue (gt) at the implant (m) interface and in the interconnected
pores (A-B). Higher magnification showed the adjacency of the bone substitution material and the lymphatics (C). A high amount of
cells with yellow granular cytoplasm were localized in the granulations tissue (D). These cells are supposed to resorb the degraded
implant.  They  are  often  found  close  to  the  lymphatic  vessels  that  sometimes  seem  to  contain  lymphocytes  (D).  Nuclei  were
counterstained with hematoxylin. Bar represents 1 mm in A, 200 µm in B, 20 µm in C-D.
doi: 10.1371/journal.pone.0077259.g009
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structure, surface to have significant impact on the mechanical
properties  degradation,  the  homeostasis  of  calcium,  and
thereby the local cell and tissue reaction at the interface [55].
Interestingly, we could not discover the porous implant in the
histological sections but granulation tissue in the fracture gap
that contained lymphatic capillaries. Accordingly, no significant
differences in comparison to the control group (4 mm defect)
were calculated. However, significant changes were detected
for the monolithic xerogels composed of the same ingredients.
The number of lymphatics found in this animal subgroup was
significant up-regulated in comparison to the control group (4
mm  defect).  The  podoplainin  staining  in  sections  of  this
subgroup  had  an  altered  image.  The  labeled  cells  were
localized directly at the interface. It appeared like an individual
labeling of the plasma membrane of a specific cell type. Since
it is well known that myofibroblasts are stained by podoplanin
[20],  [29]  and  the  presence  of  myofibroblasts  at  implant
interfaces  has  already  been  described  [56],  [57]  we
hypothesize that at the interface of the xerogel myofibroblasts
are  accumulated.  This  interesting  theory  should  further  be
analyzed studying the osseous integration and degradation of
the  xerogel  in  future  studies.  However,  some  of  the  labeling
was found in cells invading the implant. An infiltration of the
implant was also observed for the Fe-S group. All implants of
the  Fe  group  include  interconnected  pores.  Recently,
Yoshikawa  et  al.  2009  [5]  described  that  bone  substitution
materials with interconnected pores improve bony integration
by  allowing  the  immigration  of  mesenchymal  stem  cells,
granulation tissue, and vasculature into the pores. Interestingly,
the pores of the Fe-BP implant were not filled with granulation
tissue  and  therefore  no  lymphatic  vessels  were  found  there.
Sections  of  the  plain  Fe  exhibited  a  filling  of  the  pores  with
granulation tissue near the circumference of the implant. Into
this  area  also  incorporated  lymphatic  capillaries  were  found.
The highest number of infiltrating lymphatic vessels was found
in  the  Fe-S  group  showing  the  sophisticated  implant
integration.  Besides  all  Fe  implants  were  surrounded  by
granulation  tissue  including  lymphatic  capillaries  where  no
significant differences were detected.
In conclusion, our results showed that lymphatic vessels also
occur  in  damaged  bone  of  animals  where  osteoporosis  was
induced.  In  addition,  we  found  lymphatic  capillaries  in  the
fracture  gap  and  at  the  interface  of  several  implanted  bone
substitution  materials.  After  quantification  of  the  lymphatic
capillaries  we  could  speculate  about  the  progress  of  bone
Figure  10.    Iron  foam  coated  with  bisphosphonate  (Fe-BP).    Podoplanin  immunolabelling  was  observed  in  the  lymphatic
endothelial cells (arrow) that were localized in the granulation tissue (gt) at the implant interface (A-B). Cells with yellow granular
cytoplasma that might have phagocytozed the degradation products of the implant were also found at the interface (i). These cells
were often situated in direct contact with the lymphatic vessels (B). Few of them were found even in the lumen of the lymphatics
(arrowhead in C). Some of the lymphatic capillaries contained lymphocytes as determined by shape and size of their nuclei (D). s =
hole of the screw. Bar represents 1 mm in A, 20 µm in B-D.
doi: 10.1371/journal.pone.0077259.g010
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study  we  were  able  to  confirm  our  hypothesis  that  also  in
Figure 11.  Number of lymphatic vessels localized in the
interconnected pores of iron-foams.  A significant increase
was  calculated  for  the  correlation  of  the  counted  number  of
lymphatic vessels localized in the Fe-S implant in comparison
to the Fe (p = 0.004) as well as the Fe-BP implants (p = 0.001).
Data are presented as box plots with the median indicated by
solid line within the box. Small circles illustrate data beyond 3 x
standard deviation (SD). ** = p ≤ 0.01, *** = p ≤ 0.001.
doi: 10.1371/journal.pone.0077259.g011
osteoporotic  conditions  degraded  and  by  macrophages
resorbed  biomaterials  can  be  removed  from  the  implant
environment  by  lymphatic  vessels.  Therefore
lymphangiogenesis  and  migration  of  lymphatic  vessels  has
been identified as actuating variable for the design of upgraded
etiology-adapted bone substitution materials.
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